56results about How to "High neutralizing activity" patented technology

The present invention relates to a preparation method of a recombinant porcine epidemic diarrhea virus antibody. The preparation method of the recombinant porcine epidemic diarrhea virus antibody: select the mode of co-expression of antigen and antibody, and combine PEDV antigen gene S1 and anti-PEDV ScFv gene Co-expressed in the periplasmic cavity of Escherichia coli, three rounds of panning were performed by flow cytometry; the PEDV antibody was purified after expressing the ScFv gene in Escherichia coli, and the specificity of the PEDV ScFv antibody was detected by ELISA method, which was named PEDV‑ScFv; The construction of the anti-PEDV ScFv library and the preparation of the anti-PEDV antibody were carried out in two steps. The pig-derived PEDV antibody provided by the invention does not generate an immune response, is highly targeted, is easier to screen for antibodies with high neutralizing activity, and has a short preparation cycle and high speed.

The present invention discloses a monoclonal antibody 14F8 against Nipah virus envelope glycoprotein. The antibody has a unique CDR region and has a binding titer of 0.47 ng / mL with the Nipah virus envelope glycoprotein, and when an antibody concentration is greater than 9.14 ng / mL, an ELISA OD value is greater than 2.0, indicating excellent antigen binding activity. The antibody has a binding titer of 129.66 ng / mL with Hendra virus envelope glycoprotein, and when the antibody concentration is 20,000 ng / mL, the OD value is only 0.29, indicating the 14F8 can be used for detection of the Nipah virus envelope glycoprotein and can effectively distinguish the Nipah virus envelope glycoprotein and the Hendra virus envelope glycoprotein. The present invention also discloses an application of the14F8 monoclonal antibody in preparation of drugs for treating Nipah virus diseases, the antibody can effectively inhibit binding of the Nipah virus envelope glycoprotein to a cellular receptor EFNB2,an IC50 value is 50 ng / mL, besides, neutralizing activity is enhanced with increase of the antibody concentration, and when the antibody concentration exceeds 1 [mu]g / ml, an inhibition rate tends to reach 100%, indicating a prospect of the 14F8 monoclonal antibody as a candidate therapeutic antibody for the Nipah virus diseases.

The invention discloses a fully human neutralizing antibody against fusion protein of respiratory syncytial virus and application thereof. Specifically, the present invention discloses a fully human monoclonal antibody 4F1 against the fusion protein (F protein) and pre-fusion protein (preF protein) of respiratory syncytial virus, nucleic acid sequences encoding the antibody and antibody fragments, and a preparation method thereof. In vitro and in vivo experiments have confirmed that the 4F1 antibody can effectively prevent and control RSV infection. It has low immunogenicity for the human body and can avoid human-anti-mouse and other antibody-mediated immune rejection reactions. It can be used clinically For the prevention and treatment of respiratory syncytial virus infection.